Activity and Safety of Pralatrexate and Romidepsin in Patients with Relapsed/Refractory Peripheral T-Cell Lymphoma (PTCL)


Activity and Safety of Pralatrexate and Romidepsin in Patients with Relapsed/Refractory Peripheral T-Cell Lymphoma (PTCL)
Slides from a presentation at ASH 2010 and comments from a recent interview with Steven M Horwitz, MD (12/29/10)

Coiffier B et al. Final results from a pivotal, multicenter, international, open-label, phase 2 study of romidepsin in progressive or relapsed peripheral T-cell lymphoma following prior systemic therapy. Proc ASH 2010;Abstract 114.

Goy A et al. Pralatrexate is effective in patients with relapsed or refractory peripheral T-cell lymphoma (PTCL) with prior ifosfamide, carboplatin and etoposide (ICE)-based regimens. Proc ASH 2010;Abstract 1753.

Dr Horwitz is Assistant Attending in the Division of Hematologic Oncology’s Lymphoma Service at Memorial Sloan-Kettering Cancer Center in New York, New York.